AI Article Synopsis
- The study investigates the relationship between hypermethylation of the BRCA1/2 promoter genes and breast cancer in women, focusing on how this relates to age and tumor stage.
- It analyzes DNA from 50 biopsies of Moroccan women with breast cancer, revealing that 62% of samples showed BRCA1 hypermethylation, while BRCA2 was negative.
- The findings suggest that BRCA1 methylation is more prevalent in women over 47 years old, indicating that age could play a significant role in the progression of breast cancer.
Article Abstract
Background: The promoter region is a key element of gene expression regulation. In mammals, most of the genes present, at the level of their promoter, a large number of islands CpG. Age also is seen as another factor for developing breast cell cancer reaching the tumour stage.
Aim: This study aimed to explore the hypermethylation of the BRCA1/2 promoter gene in women breast cancer and correlation with age and tumour stage.
Materials And Methods: Fifty biopsies were derived from Moroccan women treated for breast carcinoma, the DNA extracted was treated by bisulphite and the targeted BRCA1/2 Amplicons were amplified by specific methylation primers (MSP).
Results: The result shows that 62% of the samples were BRCA1 methylated in addition and negative result for BRCA2, these positive epigenetic factor were remarkable in women over 47 years and at the stage of malignant tumour.
Conclusion: These results show that half of the methylated samples are positive with a majority of over 47 years old, and confirms that age might be an additional factor for breast cancer development.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11033-021-06705-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Differential methylation of circulating free DNA assessed through cfMeDiP as a new tool for breast cancer diagnosis and detection of BRCA1/2 mutation.
J Transl Med
October 2024
Sylvester Comprehensive Cancer Center and Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami, FL, USA.
Background: Recent studies have highlighted the importance of the cell-free DNA (cfDNA) methylation profile in detecting breast cancer (BC) and its different subtypes. We investigated whether plasma cfDNA methylation, using cell-free Methylated DNA Immunoprecipitation and High-Throughput Sequencing (cfMeDIP-seq), may be informative in characterizing breast cancer in patients with BRCA1/2 germline mutations for early cancer detection and response to therapy.
Methods: We enrolled 23 BC patients with germline mutation of BRCA1 and BRCA2 genes, 19 healthy controls without BRCA1/2 mutation, and two healthy individuals who carried BRCA1/2 mutations.
Subset of retinoblastoma tumours is associated with mutations.
Br J Ophthalmol
June 2024
Department of Ophthalmology, Institute of Vision Research, Yonsei University College of Medicine, Seoul, Republic of Korea
Article Synopsis
- * Out of 30 retinoblastoma patients tested, 20% had germline variants in BRCA1/2 or BRIP1 genes, with some variants classified as pathogenic and others showing potential pathogenicity through alternative analysis.
- * Findings from a detailed genetic analysis of one patient revealed significant mutations, including the loss of one RB1 allele and evidence of gene promoter hypermethylation, suggesting complex genetic and epigenetic factors in retinoblastoma development.
Clinical Relevance of BRCA1 Promoter Methylation Testing in Patients with Ovarian Cancer.
Clin Cancer Res
August 2023
Medical Oncology Department, Gynecology Unit, Institut Gustave Roussy, Villejuif, France.
Purpose: Homologous recombination deficiency (HRD) is closely related to PARP inhibitor (PARPi) benefit in ovarian cancer. The capacity of BRCA1 promoter methylation to predict prognosis and HRD status remains unclear. We aimed to correlate BRCA1 promoter methylation levels in patients with high-grade ovarian cancer to HRD status and clinical behavior to assess its clinical relevance.
View Article and Find Full Text PDFThe BRCAness Landscape of Cancer.
Cells
December 2022
MoE Frontiers Science Center for Precision Oncology, Cancer Centre and Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau 999078, China.
BRCAness refers to the damaged homologous recombination (HR) function due to the defects in HR-involved non- genes. BRCAness is the important marker for the use of synthetic lethal-based PARP inhibitor therapy in breast and ovarian cancer treatment. The success provides an opportunity of applying PARP inhibitor therapy to treat other cancer types with BRCAness features.
View Article and Find Full Text PDFAlterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial.
J Pers Med
September 2022
Department of Medical Oncology, Centre Léon Bérard, 69008 Lyon, France.
Article Synopsis
- A specific type of metastatic triple-negative breast cancer (mTNBC) shows increased sensitivity to platinum-based chemotherapy due to homologous recombination deficiency (HRD), prompting a study to explore genetic alterations and their impact on treatment response.
- In a study involving mTNBC patients, tumors were analyzed for mutations in 19 HRR genes, and patients were grouped based on their molecular status to evaluate responses to platinum therapy.
- Results indicated that mutations in specific HRR genes and promoter methylation were linked to better disease control, suggesting that broader genetic evaluations could help identify more patients who might benefit from platinum treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!